Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.59 |
| ▸ | CTSS | P25774 | 1/20 | 0.59 |
| ▸ | CTSK | P43235 | 1/20 | 0.59 |
| ▸ | TACR1 | P25103 | 8/20 | 0.57 |
| ▸ | TACR3 | P29371 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CCKBR | P32239 | 2/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3020291 | 1.00 | CTSL (0.59) | CTSLCTSSCTSKTACR1TACR3 | |
| SCHEMBL9016089 | 1.00 | CTSL (0.59) | CTSLCTSSCTSKTACR1TACR3 | |
| SCHEMBL16694906 | 0.90 | TACR1 (0.56) | CTSLCTSSCTSKTACR1TACR3 | |
| SCHEMBL10625966 | 0.90 | TACR1 (0.52) | CTSLCTSSCTSKTACR1TACR3 | |
| SCHEMBL10625499 | 0.89 | TACR1 (0.52) | CTSLCTSSCTSKTACR1TACR3 | |
| SCHEMBL10625491 | 0.89 | TACR1 (0.52) | CTSLCTSSCTSKTACR1TACR3 | |
| SCHEMBL8651829 | 0.87 | CTSL (0.58) | CTSLCTSSCTSKTACR1TACR3 | |
| SCHEMBL10746226 | 0.86 | TACR1 (0.48) | CTSLCTSSCTSKTACR1TACR3 | |
| SCHEMBL8650748 | 0.86 | CTSL (0.57) | CTSLCTSSCTSKTACR1TACR3 | |
| SCHEMBL9016095 | 0.85 | TACR1 (0.74) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2871181-B1 | Novel Compounds for Regeneration of Terminally-Differentiated Cells and tissues | ACOUSIA THERAPEUTICS GMBH (DE) | 2016-10-05 | — | — | EP | disclosed |
| US-20160280670-A1 | NOVEL COMPOUNDS FOR REGENERATION OF TERMINALLY-DIFFERENTIATED CELLS AND TISSUES | ACOUSIA THERAPEUTICS GMBH (DE) | 2016-09-29 | — | — | US | disclosed |
| WO-2015071165-A1 | NOVEL COMPOUNDS FOR REGENERATION OF TERMINALLY-DIFFERENTIATED CELLS AND TISSUES | ACOUSIA THERAPEUTICS GMBH (DE) | 2015-05-21 | — | — | WO | disclosed |
| EP-2871181-A1 | Novel Compounds for Regeneration of Terminally-Differentiated Cells and tissues | Acousia Therapeutics GmbH (DE) | 2015-05-13 | — | — | EP | disclosed |
| US-20100184758-A1 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-07-22 | — | — | US | disclosed |
| EP-2178537-A1 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009011836-A1 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK & CO., INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| EP-0920424-B1 | NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2005-11-30 | — | — | EP | disclosed |
| US-6194437-B1 | ANTIDEPRESSANTS; ANTICANCER AGENTS; GASTROINTESTINAL DISORDERS; COGNITION ACTIVATORS | WARNER-LAMBERT COMPANY | 2001-02-27 | — | — | US | disclosed |
| EP-0920424-A1 | NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998007718-A1 | NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-02-26 | — | — | WO | disclosed |
| EP-0563132-B1 | TETRAPEPTIDE DERIVATIVES AND ANALOGUES | BLACK JAMES FOUNDATION (GB) | 1996-02-07 | — | — | EP | disclosed |
| US-5486597-A | GASTRIN ANTAGONIST AS ANTISECRETORY AGENTS OF GASTRIC JUICE FOR STOMACH CANCER | JAMES BLACK FOUNDATION LIMITED (GB) | 1996-01-23 | — | — | US | disclosed |
| EP-0563132-A1 | TETRAPEPTIDE DERIVATIVES AND ANALOGUES. | BLACK JAMES FOUNDATION (GB) | 1993-10-06 | — | — | EP | disclosed |
| WO-1992011284-A1 | TETRAPEPTIDE DERIVATIVES AND ANALOGUES | THE JAMES BLACK FOUNDATION LIMITED (GB) | 1992-07-09 | — | — | WO | disclosed |
| US-4757151-A | Pharmaceuticals | WARNER-LAMBERT COMPANY (US) | 1988-07-12 | — | — | US | disclosed |
| EP-0224151-A2 | 2-Substituted-[2-substituted-amino]-N-aralkyl-3-[indol-3-yl]propanamides | WARNER-LAMBERT COMPANY (US) | 1987-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184758-A1 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | GPR119, SSTR3, SSTR2 | CTSL 2708/4885CTSS 2931/4885CTSK 3358/4885 |
| US-20160280670-A1 | NOVEL COMPOUNDS FOR REGENERATION OF TERMINALLY-DIFFERENTIATED CELLS AND TISSUES | CCNB3, CCNB1, CCNB2 | CTSL 1585/4885CTSS 1190/4885CTSK 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.